|
1
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sultana A, Smith CT, Cunningham D,
Starling N, Neoptolemos JP and Ghaneh P: Meta-analyses of
chemotherapy for locally advanced and metastatic pancreatic cancer.
J Clin Oncol. 25:2607–2615. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
national cancer institute of Canada clinical trials group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weigel PH and DeAngelis PL: Hyaluronan
synthases: A decade-plus of novel glycosyltransferases. J Biol
Chem. 282:36777–36781. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tammi RH, Passi AG, Rilla K, Karousou E,
Vigetti D, Makkonen K and Tammi MI: Transcriptional and
post-translational regulation of hyaluronan synthesis. FEBS J.
278:1419–1428. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Entwistle J, Hall CL and Turley EA: HA
receptors: Regulators of signalling to the cytoskeleton. J Cell
Biochem. 61:569–577. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Adamia S, Maxwell CA and Pilarski LM:
Hyaluronan and hyaluronan synthases: Potential therapeutic targets
in cancer. Curr Drug Targets Cardiovasc Haematol Disord. 5:3–14.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Toole BP: Hyaluronan promotes the
malignant phenotype. Glycobiology. 12:37R–42R. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mahlbacher V, Sewing A, Elsässer HP and
Kern HF: Hyaluronan is a secretory product of human pancreatic
adenocarcinoma cells. Eur J Cell Biol. 58:28–34. 1992.PubMed/NCBI
|
|
11
|
Fries H, Elsässer HP, Mahlbacher V,
Neumann K and Kern HF: Localisation of hyaluronate (HA) in primary
tumors and nude mouse xenografts of human pancreatic carcinomas
using a biotinylated HA-binding protein. Virchows Arch. 424:7–12.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McBride WH and Bard JB:
Hyaluronidase-sensitive halos around adherent cells. Their role in
blocking lymphocyte-mediated cytolysis. J Exp Med. 149:507–515.
1979. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Suzuki Y, Nishida Y, Naruse T, Gemba T and
Ishiguro N: Pericellular matrix formation alters the efficiency of
intracellular uptake of oligonucleotides in osteosarcoma cells. J
Surg Res. 152:148–156. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Toole BP: Hyaluronan-CD44 interactions in
cancer: Paradoxes and possibilities. Clin Cancer Res. 15:7462–7468.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheng XB, Sato N, Kohi S and Yamaguchi K:
Prognostic impact of hyaluronan and its regulators in pancreatic
ductal adenocarcinoma. PLoS One. 8:e807652013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nakamura T, Takagaki K, Shibata S, Tanaka
K, Higuchi T and Endo M: Hyaluronic-acid-deficient extracellular
matrix induced by addition of 4-methylumbelliferone to the medium
of cultured human skin fibroblasts. Biochem Biophys Res Commun.
208:470–475. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakamura T, Funahashi M, Takagaki K,
Munakata H, Tanaka K, Saito Y and Endo M: Effect of
4-methylumbelliferone on cell-free synthesis of hyaluronic acid.
Biochem Mol Biol Int. 43:263–268. 1997.PubMed/NCBI
|
|
18
|
Kakizaki I, Takagaki K, Endo Y, Kudo D,
Ikeya H, Miyoshi T, Baggenstoss BA, Tlapak-Simmons VL, Kumari K,
Nakane A, et al: Inhibition of hyaluronan synthesis in
Streptococcus equi FM100 by 4-methylumbelliferone. Eur J Biochem.
269:5066–5075. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kudo D, Kon A, Yoshihara S, Kakizaki I,
Sasaki M, Endo M and Takagaki K: Effect of a hyaluronan synthase
suppressor, 4-methylumbelliferone, on B16F-10 melanoma cell
adhesion and locomotion. Biochem Biophys Res Commun. 321:783–787.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kakizaki I, Kojima K, Takagaki K, Endo M,
Kannagi R, Ito M, Maruo Y, Sato H, Yasuda T, Mita S, et al: A novel
mechanism for the inhibition of hyaluronan biosynthesis by
4-methylumbelliferone. J Biol Chem. 279:33281–33289. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoshihara S, Kon A, Kudo D, Nakazawa H,
Kakizaki I, Sasaki M, Endo M and Takagaki K: A hyaluronan synthase
suppressor, 4-methylumbelliferone, inhibits liver metastasis of
melanoma cells. FEBS Lett. 579:2722–2726. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Morohashi H, Kon A, Nakai M, Yamaguchi M,
Kakizaki I, Yoshihara S, Sasaki M and Takagaki K: Study of
hyaluronan synthase inhibitor, 4-methylumbelliferone derivatives on
human pancreatic cancer cell (KP1-NL). Biochem Biophys Res Commun.
345:1454–1459. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nakazawa H, Yoshihara S, Kudo D, Morohashi
H, Kakizaki I, Kon A, Takagaki K and Sasaki M:
4-methylumbelliferone, a hyaluronan synthase suppressor, enhances
the anticancer activity of gemcitabine in human pancreatic cancer
cells. Cancer Chemother Pharmacol. 57:165–170. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vigetti D, Rizzi M, Viola M, Karousou E,
Genasetti A, Clerici M, Bartolini B, Hascall VC, De Luca G and
Passi A: The effects of 4-methylumbelliferone on hyaluronan
synthesis, MMP2 activity, proliferation, and motility of human
aortic smooth muscle cells. Glycobiology. 19:537–546. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kultti A, Pasonen-Seppänen S, Jauhiainen
M, Rilla KJ, Kärnä R, Pyöriä E, Tammi RH and Tammi MI:
4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of
cellular UDP-glucuronic acid and downregulation of hyaluronan
synthase 2 and 3. Exp Cell Res. 315:1914–1923. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lokeshwar VB, Lopez LE, Munoz D, Chi A,
Shirodkar SP, Lokeshwar SD, Escudero DO, Dhir N and Altman N:
Antitumor activity of hyaluronic acid synthesis inhibitor
4-methylumbelliferone in prostate cancer cells. Cancer Res.
70:2613–2623. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Twarock S, Freudenberger T, Poscher E, Dai
G, Jannasch K, Dullin C, Alves F, Prenzel K, Knoefel WT, Stoecklein
NH, et al: Inhibition of oesophageal squamous cell carcinoma
progression by in vivo targeting of hyaluronan synthesis. Mol
Cancer. 10:302011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Urakawa H, Nishida Y, Wasa J, Arai E, Zhuo
L, Kimata K, Kozawa E, Futamura N and Ishiguro N: Inhibition of
hyaluronan synthesis in breast cancer cells by
4-methylumbelliferone suppresses tumorigenicity in vitro and
metastatic lesions of bone in vivo. Int J Cancer. 130:454–466.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakamura R, Kuwabara H, Yoneda M,
Yoshihara S, Ishikawa T, Miura T, Nozaka H, Nanashima N, Sato T and
Nakamura T: Suppression of matrix metalloproteinase-9 by
4-methylumbelliferone. Cell Biol Int. 31:1022–1026. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nakamura T, Ishikawa T, Nanashima N, Miura
T, Nozaka H, Nakaoka R and Sato T: 4-Methylumbelliferone induces
the expression of membrane type 1-matrix metalloproteinase in
cultured human skin fibroblasts. Biochem Biophys Res Commun.
298:646–650. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kuwabara H, Yoneda M, Hayasaki H, Nakamura
T and Shibayama Y: A hyaluronan synthase suppressor,
4-methylumbelliferone, inhibits the tumor invasion associated with
N-cadherin decreasement. Pathol Int. 61:262–263. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Holm Svensson AC, Bengtsson T, Grenegård M
and Lindström EG: Hyaluronic acid influence on platelet-induced
airway smooth muscle cell proliferation. Exp Cell Res. 318:632–640.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Twarock S, Tammi MI, Savani RC and Fischer
JW: Hyaluronan stabilizes focal adhesions, filopodia, and the
proliferative phenotype in esophageal squamous carcinoma cells. J
Biol Chem. 285:23276–23284. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheng XB, Sato N, Kohi S, Koga A and
Hirata K: Receptor for hyaluronic acid-mediated motility is
associated with poor survival in pancreatic ductal adenocarcinoma.
J Cancer. 6:1093–1098. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Knudson W, Biswas C and Toole BP:
Interactions between human tumor cells and fibroblasts stimulate
hyaluronate synthesis. Proc Natl Acad Sci USA. 81:6767–6771. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sugahara KN, Murai T, Nishinakamura H,
Kawashima H, Saya H and Miyasaka M: Hyaluronan oligosaccharides
induce CD44 cleavage and promote cell migration in CD44-expressing
tumor cells. J Biol Chem. 278:32259–32265. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu M, Cao M, He Y, Liu Y, Yang C, Du Y,
Wang W and Gao F: A novel role of low molecular weight hyaluronan
in breast cancer metastasis. FASEB J. 29:1290–1298. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schmaus A, Klusmeier S, Rothley M, Dimmler
A, Sipos B, Faller G, Thiele W, Allgayer H, Hohenberger P, Post S
and Sleeman JP: Accumulation of small hyaluronan oligosaccharides
in tumour interstitial fluid correlates with lymphatic invasion and
lymph node metastasis. Br J Cancer. 111:559–567. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fontaine L, Grand M, Molho D and Boschetti
E: Spasmolytic activity of 4-methylumbelliferone on Oddi's
sphincter. Studies on the mode of action of the drug. Therapie.
23:63–74. 1968.(In French). PubMed/NCBI
|
|
40
|
Fontaine L, Grand M, Molho D, Chabert MJ
and Boschetti E: Choleretic, spasmolytic and general pharmacologic
activities of 4-methylumbelliferone. Therapie. 23:51–62. 1968.(In
French). PubMed/NCBI
|
